Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Gross Profit (2019 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Gross Profit for 5 consecutive years, with $32.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gross Profit rose 206.03% year-over-year to $32.6 million, compared with a TTM value of $90.0 million through Dec 2025, up 455.84%, and an annual FY2025 reading of $90.0 million, up 455.84% over the prior year.
  • Gross Profit was $32.6 million for Q4 2025 at Zevra Therapeutics, up from $24.9 million in the prior quarter.
  • Across five years, Gross Profit topped out at $32.6 million in Q4 2025 and bottomed at -$3000.0 in Q2 2022.
  • Average Gross Profit over 5 years is $7.9 million, with a median of $2.9 million recorded in 2023.
  • The sharpest move saw Gross Profit surged 259866.67% in 2023, then plummeted 88.76% in 2024.
  • Year by year, Gross Profit stood at $2.5 million in 2021, then fell by 8.96% to $2.3 million in 2022, then soared by 409.06% to $11.7 million in 2023, then dropped by 8.95% to $10.6 million in 2024, then skyrocketed by 206.03% to $32.6 million in 2025.
  • Business Quant data shows Gross Profit for ZVRA at $32.6 million in Q4 2025, $24.9 million in Q3 2025, and $13.5 million in Q2 2025.